Angioedema induced by cardiovascular drugs: New players join old friends

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 10, 2015, Pages 1196-1200

  Bas, M ^a   Greve, J ^b   Strassen, U ^a   Khosravani, F ^c   Hoffmann, T K ^b   Kojda, G ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

ACE inhibitor; angioedema; bradykinin type 2 receptor; icatibant; sacubitril

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENKEPHALINASE INHIBITOR;

ANGIONEUROTIC EDEMA; ENZYME ACTIVATION; HEART FAILURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; ANGIOEDEMA; DRUG EFFECTS; METABOLISM;

ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; CARDIOVASCULAR AGENTS; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84942337324     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12680     Document Type: Review

References (37)

1. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G,. Non-allergic angioedema. Role of bradykinin. Allergy 2007; 62: 842-856.
2. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM,. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-1219.
3. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al., Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-1183.
4. Oike Y, Ogata Y, Higashi D, Matsumura T, Numata Y,. Fatal angioedema associated with enalapril. Intern Med 1993; 32: 308-310.
5. Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr,. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 2008; 100: 327-332.
6. Dean DE, Schultz DL, Powers RH,. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 2001; 46: 1239-1243.
7. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G,. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
9. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al., Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
10. Ulmer JL, Garvey MJ,. Fatal angioedema associated with lisinopril. Ann Pharmacother 1992; 26: 1245-1246.
11. Agostoni A, Cicardi M,. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-215.
12. Farkas H, Harmat G, Fust G, Varga L, Visy B,. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 2002; 13: 153-161.
13. Bork K, Barnstedt SE, Koch P, Traupe H,. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213-217.
14. Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, et al., Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104.
15. Bork K, Wulff K, Witzke G, Hardt J,. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy 2015. 70: 1004-1012.
16. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III,. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-1063.
17. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, et al., Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-268.
18. Erdos EG, Tan F, Skidgel RA,. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010; 55: 214-220.
19. Khosravani F, Suvorava T, Dao VT, Brockmann N, Kocgirli O, Herbst FF, et al., Stability of murine bradykinin type 2 receptor despite treatment with NO, bradykinin, icatibant, or C1-INH. Allergy 2015; 70: 285-294.
20. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al., Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
21. Bas M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, et al., A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 2015; 372: 418-425.
22. Greve J, Bas M, Hoffmann TK, Schuler PJ, Weller P, Kojda G, et al., Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope 2015; 125: E198-202
23. Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G,. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998; 32: 1787-1796.
24. Hornig B, Kohler C, Schlink D, Tatge H, Drexler H,. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism. Hypertension 2003; 41: 1092-1095.
25. Campbell DJ, Krum H, Esler MD,. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005; 111: 315-320.
26. Hunley TE, Tamura M, Stoneking BJ, Nishimura H, Ichiki T, Inagami T, et al., The angiotensin type II receptor tonically inhibits angiotensin- converting enzyme in AT2 null mutant mice. Kidney Int 2000; 57: 570-577.
27. Strassen U, Bas M, Hoffmann TK, Knopf A, Greve J,. Treatment of angiotensin receptor blocker-induced Angioedema: a case series. Laryngoscope 2015; 125: 1619-1623.
28. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ,. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol 2008; 101: 495-499.
29. Hellebrand MC, Kojda G, Hoffmann TK, Bas M,. [Angioedema due to ACE inhibitors and AT(1) receptor antagonists.]. Hautarzt 2005; 57: 808-810. German.
30. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al., Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
31. Schmidt WE, Siegel EG, Creutzfeldt W,. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28: 704-707.
32. Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, et al., Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol 2007; 120: 403-408.
33. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA,. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009; 54: 516-523.
34. von Lueder TG, Atar D, Krum H,. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014; 144: 41-49.
35. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al., Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
36. Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ,. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 1996; 2: 814-817.
37. Sabrane K, Kruse MN, Gazinski A, Kuhn M,. Chronic endothelium-dependent regulation of arterial blood pressure by atrial natriuretic peptide: role of nitric oxide and endothelin-1. Endocrinology 2009; 150: 2382-2387.